Zoetis recently released a new beta agonist, Actogain 45, (ractopamine hydrochloride) for feedyard use, and during the recent Academy of Veterinary Consultants conference, Zoetis technical services veterinarian Marilyn Corbin, DVM, PhD, outlined trial results for the product.

Corbin says Actogain 45 is a “bioequivalent” product to Optaflexx, a proven ractopamine product marketed by Elanco. As such, the FDA approval process required the company to prove the product’s active and inactive ingredients and manufacturing process are essentially equivalent to those for Optaflexx. After the the product met those bioequivalence standards for approval, Zoetis voluntarily conducted a series of feedyard trials to demonstrate its efficacy compared with controls and the legacy product.

Actogain 45 is intended to increase average daily gains, improve feed efficiency and increase lean-meat yield during the final 28 to 42 days of the feeding period. The product is approved to be fed in combination with Rumensin, Rumensin and Tylan, Rumensin and MGA or Rumensin, Tylan and MGA. It is approved for use in steers and heifers and has a zero-day pre-slaughter withdrawal allowing flexibility in marketing finished cattle.

Corbin outlined three trials in feedyards in Idaho, Texas and Washington comparing gains, feed efficiency, finished weights and carcass quality between Actogain 45 and control cattle receiving no beta agonist, or between Actogain 45, control cattle and cattle fed Optaflexx at the same dose and duration.

In each of the trials, Actogain provided about a 17-pound live-weight advantage and 11-pound carcass-weight advantage over controls, along with a 15 percent improvement in feed efficiency with minimal impact on carcass grade. In direct comparisons with Optaflexx, researchers found no statistically significant differences between the two products in terms of live weight, carcass weight or feed efficiency.

Corbin says Actogain 45 is priced competitively to Optaflexx.